Kynam Capital Management, LP Syndax Pharmaceuticals Inc Transaction History
Kynam Capital Management, LP
- $1.58 Billion
- Q4 2024
A detailed history of Kynam Capital Management, LP transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Kynam Capital Management, LP holds 8,520,000 shares of SNDX stock, worth $115 Million. This represents 7.14% of its overall portfolio holdings.
Number of Shares
8,520,000
Previous 5,842,925
45.82%
Holding current value
$115 Million
Previous $112 Million
0.14%
% of portfolio
7.14%
Previous 9.23%
Shares
12 transactions
Others Institutions Holding SNDX
# of Institutions
232Shares Held
92.7MCall Options Held
1.39MPut Options Held
543K-
Black Rock Inc. New York, NY7.91MShares$106 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.95MShares$80 Million0.01% of portfolio
-
Morgan Stanley New York, NY5.31MShares$71.4 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.88MShares$65.6 Million0.0% of portfolio
-
State Street Corp Boston, MA3.92MShares$52.7 Million0.0% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $760M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...